PTCT Q1 2026 Earnings Report and Guidance Update
Parsley Therapeutics (NASDAQ: PTCT) reported first-quarter revenue of $273 million, with strong growth in Sephience Global Revenue at 36% quarter-over-quarter. The company raised its full-year product revenue guidance to between $750 million and $850 million.
Tickers: $PTCT
Topics: geographic_expansion guidance_update patient_uptake revenue